Trial Search Results

Memantine Augmentation in Obsessive-Compulsive Disorder

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: Memantine

Phase:

Phase 1/Phase 2

Eligibility


Inclusion Criteria:

   - at least 18 years of age

   - suffering from OCD

   - Y-BOCS score of 18 or greater

   - taking a therapeutic dose of an anti-OCD medication specified in the protocol

Exclusion Criteria:

   - diagnosed with a mental disorder other than OCD

   - taking tiagabine or pregabalin

   - having had a previous trial of memantine

   - receiving therapy for OCD

   - substance abuse in the last 6 months

   - personality disorders sufficiently severe to interfere with study participation

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Nona Gamel
6507238601
Not Recruiting